---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-097152"
form_type: "8-K"
ticker: "VYGR"
cik: "0001640266"
company_name: "Voyager Therapeutics, Inc."
filed_at: "2024-09-05T23:59:59+00:00"
generated_at: "2026-05-31T06:15:30.243202+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Voyager grants Novartis license to capsid for gene therapy; $15M upfront, up to $305M milestones

## Summary
- Novartis receives exclusive license to a capsid from Voyager's TRACER platform for a single gene target.
- One-time $15M fee paid upfront; Voyager eligible for $130M in development/regulatory/commercial milestones.
- Additional sales milestones up to $175M per product plus tiered mid- to high-single-digit royalties.
- Novartis' prior option rights for other targets expired as of September 3, 2024.

## SEC filing metadata
- accession: 0001104659-24-097152
- form_type: 8-K
- ticker: VYGR
- cik: 0001640266
- company_name: Voyager Therapeutics, Inc.
- filed_at: 2024-09-05T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1640266/000110465924097152/0001104659-24-097152-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1640266/000110465924097152/tm2423222d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-097152
- JSON: https://secwatch.observer/filing/0001104659-24-097152.json
- Plain text: https://secwatch.observer/filing/0001104659-24-097152.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.